Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial. J of Skin [Internet]. 2024 Nov. 18 [cited 2025 Nov. 7];8(6):s445. Available from: https://skin.dermsquared.com/skin/article/view/3082